Search Results - "Büller, H R"

Venous thromboembolism in cancer patients: a population-based cohort study by Mulder, F.I., Horváth-Puhó, E., van Es, N., van Laarhoven, H.W.M., Pedersen, L., Moik, F., Ay, C., Büller, H.R., Sørensen, H.T.

“…The incidence of venous thromboembolism (VTE) in cancer patients may have changed in the past decade, possibly due to novel cancer therapies, improved…”
Get full text

International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer by FARGE, D., DEBOURDEAU, P., BECKERS, M., BAGLIN, C., BAUERSACHS, R. M., BRENNER, B., BRILHANTE, D., FALANGA, A., GEROTZAFIAS, G. T., HAIM, N., KAKKAR, A. K., KHORANA, A. A., LECUMBERRI, R., MANDALA, M., MARTY, M., MONREAL, M., MOUSA, S. A., NOBLE, S., PABINGER, I., PRANDONI, P., PRINS, M. H., QARI, M. H., STREIFF, M. B., SYRIGOS, K., BOUNAMEAUX, H., BÜLLER, H. R.

“…Background: Guidelines addressing the management of venous thromboembolism (VTE) in cancer patients are heterogeneous and their implementation has been…”
Get full text

ADAMTS‐13 and von Willebrand factor predict venous thromboembolism in patients with cancer by Pépin, M., Kleinjan, A., Hajage, D., Büller, H. R., Di Nisio, M., Kamphuisen, P. W., Salomon, L., Veyradier, A., Stepanian, A., Mahé, I.

“…Essentials Cancer patients are at high risk of venous thromboembolism (VTE). In this study, cases and controls were cancer patients who did or did not develop…”
Get full text

International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer by DEBOURDEAU, P., FARGE, D., BECKERS, M., BAGLIN, C., BAUERSACHS, R. M., BRENNER, B., BRILHANTE, D., FALANGA, A., GEROTZAFIAS, G. T., HAIM, N., KAKKAR, A. K., KHORANA, A. A., LECUMBERRI, R., MANDALA, M., MARTY, M., MONREAL, M., MOUSA, S. A., NOBLE, S., PABINGER, I., PRANDONI, P., PRINS, M. H., QARI, M. H., STREIFF, M. B., SYRIGOS, K., BÜLLER, H. R., BOUNAMEAUX, H.

“…Background: Although long‐term indwelling central venous catheters (CVCs) may lead to pulmonary embolism (PE) and loss of the CVC, there is lack of consensus…”
Get full text

The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH by Ageno, W., Squizzato, A., Wells, P. S., Büller, H. R., Johnson, G.

Get full text

The original and simplified Wells rules and age‐adjusted D‐dimer testing to rule out pulmonary embolism: an individual patient data meta‐analysis by Es, N., Kraaijpoel, N., Klok, F. A., Huisman, M. V., Den Exter, P. L., Mos, I. C. M., Galipienzo, J., Büller, H. R., Bossuyt, P. M.

“…Essentials Evidence for the simplified Wells rule in ruling out acute pulmonary embolism (PE) is scarce. This was a post‐hoc analysis on data from 6 studies…”
Get full text

NOACs replace VKA as preferred oral anticoagulant among new patients: a drug utilization study in 560 pharmacies in The Netherlands by van den Heuvel, J M, Hövels, A M, Büller, H R, Mantel-Teeuwisse, A K, de Boer, A, Maitland-van der Zee, A H

“…In 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral…”
Get full text

The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer by van Es, N, Franke, V, Middeldorp, S, Wilmink, J.W, Büller, H.R

“…Abstract Background The Khorana score is a clinical prediction score developed to identify ambulatory cancer patients at high risk of venous thromboembolism…”
Get full text

Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial by ERIKSSON, B. I., DAHL, O. E., ROSENCHER, N., KURTH, A. A., VAN DIJK, C. N., FROSTICK, S. P., KÄLEBO, P., CHRISTIANSEN, A. V., HANTEL, S., HETTIARACHCHI, R., SCHNEE, J., BÜLLER, H. R.

“…Background: Oral anticoagulants, such as dabigatran etexilate, an oral, direct thrombin inhibitor, that do not require monitoring or dose adjustment offer…”
Get full text

Abnormal vaginal bleeding in women of reproductive age treated with edoxaban or warfarin for venous thromboembolism: a post hoc analysis of the Hokusai‐VTE study by Scheres, LJJ, Brekelmans, MPA, Ageno, W, Ay, C, Büller, HR, Eichinger, S, Hutten, BA, Klok, FA, Middeldorp, S, Schreiber, K, Stach, K, Blondon, M, Delluc, A

“…Objective To investigate the characteristics and outcome of abnormal vaginal bleeding in women receiving edoxaban or warfarin for treatment of venous…”
Get full text

Clinical review : Thyroid dysfunction and effects on coagulation and fibrinolysis: A systematic review by SQUIZZATO, A, ROMUALDI, E, BÜLLER, H. R, GERDES, V. E. A

“…Various changes in the coagulation-fibrinolytic system have been described in patients with an excess or deficiency of thyroid hormones. The purpose of this…”
Get full text

Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study by Mulder, F.I., van Es, N., Kraaijpoel, N., Di Nisio, M., Carrier, M., Duggal, A., Gaddh, M., Garcia, D., Grosso, M.A., Kakkar, A.K., Mercuri, M.F., Middeldorp, S., Royle, G., Segers, A., Shivakumar, S., Verhamme, P., Wang, T., Weitz, J.I., Zhang, G., Büller, H.R., Raskob, G.

“…The safety and efficacy of edoxaban and dalteparin is unclear for several cancer groups. We evaluated the occurrence of the primary outcome in large cancer…”
Get full text

D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial by Cohen, A. T., Spiro, T.E., Spyropoulos, A. C., DeSanctis, Y. H., Homering, M., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Tapson, V. F., Burton, P.

“…Summary Background D‐dimer concentrations have not been evaluated extensively as a predictor of increased venous thromboembolism (VTE) risk in acutely ill,…”
Get full text

Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists by Eerenberg, E. S., Middeldorp, S., Levi, M., Lensing, A. W., Büller, H. R.

“…Summary Background Rivaroxaban is a new oral anticoagulant (NOAC) that can be prescribed in a fixed dose, making regular monitoring and dose adjustments…”
Get full text

Sex‐specific differences in the presenting location of a first venous thromboembolism by Scheres, L. J. J., Brekelmans, M. P. A., Beenen, L. F. M., Büller, H. R., Cannegieter, S. C., Middeldorp, S.

“…Essentials Whether the location of venous thromboembolism (VTE) differs between the sexes is not known. Pulmonary embolism as presenting location was…”
Get full text

Systematic review on the effect of glucocorticoid use on procoagulant, anti‐coagulant and fibrinolytic factors by VAN ZAANE, B., NUR, E., SQUIZZATO, A., GERDES, V. E. A., BÜLLER, H. R., DEKKERS, O. M., BRANDJES, D. P. M.

“…Background: Whether glucocorticoid use contributes to a hypercoagulable state, and thereby enhances the thrombotic risk, is controversial. Objective: We aimed…”
Get full text

Diagnostic accuracy of D‐dimer test for exclusion of venous thromboembolism: a systematic review by DI NISIO, M., SQUIZZATO, A., RUTJES, A. W. S., BÜLLER, H. R., ZWINDERMAN, A. H., BOSSUYT, P. M. M.

“…Background: The reported diagnostic accuracy of the D‐dimer test for exclusion of deep vein thrombosis (DVT) and pulmonary embolism (PE) varies. It is unknown…”
Get full text

Targeted inhibition of gut microbiota proteins involved in TMAO production to reduce platelet aggregation and arterial thrombosis: a blueprint for drugging the microbiota in the treatment of cardiometabolic disease? by Mens, T. E., Büller, H. R., Nieuwdorp, M.

Get full text

Improving the diagnostic management of upper extremity deep vein thrombosis by Es, N., Bleker, S. M., Di Nisio, M., Kleinjan, A., Beyer‐Westendorf, J., Camporese, G., Aggarwal, A., Verhamme, P., Righini, M., Büller, H. R., Bossuyt, P. M.

“…Essentials The Constans score and D‐dimer can rule out upper extremity deep vein thrombosis without imaging. We evaluated the performance of an extended…”
Get full text

A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial by ERIKSSON, B. I., DAHL, O. E., BÜLLER, H. R., HETTIARACHCHI, R., ROSENCHER, N., BRAVO, M‐L., AHNFELT, L., PIOVELLA, F., STANGIER, J., KÄLEBO, P., REILLY, P.

“…Background: Dabigatran etexilate is an oral direct thrombin inhibitor undergoing evaluation for the prevention of venous thromboembolism (VTE) following…”
Get full text